1. Scrip
  2. >>Business
  3. >>Financing

Year Ahead Could Prove Rough For Private Biotech Financing

Financing Forecast: Industry Experts Have Grim Outlook For Private Biotechs

 
• By Alaric DeArment

The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.

• Source: Shutterstock

By most measures, 2022 was a good year for venture capital funds that invest in health care companies, with the total amount of capital raised last year coming in second only to the record-setting figure for 2021. But the strength of the year was front-end loaded and the amounts raised by health care investment firms declined in both the number of new funds and dollar figures during the last two quarters of 2022, falling below the quarterly average for 2020.

Consequently, speakers on a panel at the Biotechnology Innovation Organization’s BIO CEO & Investor Conference said they see difficult times...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By Mandy Jackson

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 
• By Dexter Jie Yan

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.